Immunotherapy efficacy and gender: discovery in precision medicine.
作者信息
Ulrich Bryan C, Guibert Nicolas
机构信息
Emory School of Medicine, Atlanta, GA, USA.
Thoracic Oncology Department, Larrey Hospital, University Hospital of Toulouse, Toulouse, France.
出版信息
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S211-S213. doi: 10.21037/tlcr.2018.08.05.
Abstract
摘要
相似文献
1
Immunotherapy efficacy and gender: discovery in precision medicine.免疫疗法疗效与性别：精准医学中的发现
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S211-S213. doi: 10.21037/tlcr.2018.08.05.
2
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.迈向临床精准医学：从生物标志物发现到新型治疗方法。
Trends Pharmacol Sci. 2017 Jan;38(1):25-40. doi: 10.1016/j.tips.2016.10.012. Epub 2016 Nov 18.
3
Noninvasive imaging in cancer immunotherapy: The way to precision medicine.癌症免疫治疗中的无创影像学：迈向精准医学之路。
Cancer Lett. 2019 Dec 1;466:13-22. doi: 10.1016/j.canlet.2019.08.009. Epub 2019 Sep 6.
4
Precision medicine in breast cancer: reality or utopia?乳腺癌的精准医学：现实还是乌托邦？
J Transl Med. 2017 Jun 17;15(1):139. doi: 10.1186/s12967-017-1239-z.
5
Immunotherapy in glioblastoma: emerging options in precision medicine.胶质母细胞瘤中的免疫疗法：精准医学中的新兴选择
CNS Oncol. 2016 Jul;5(3):175-86. doi: 10.2217/cns-2016-0009. Epub 2016 May 26.
6
Precision Medicine: Update on Diagnosis and Therapeutic Strategies of Hepatocellular Carcinoma.精准医学：肝细胞癌的诊断和治疗策略更新。
Curr Med Chem. 2018;25(17):1999-2008. doi: 10.2174/0929867325666180117101532.
7
Precision Medicine-Enabled Cancer Immunotherapy.精准医学助力的癌症免疫疗法
Cancer Treat Res. 2019;178:189-205. doi: 10.1007/978-3-030-16391-4_7.
8
Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy.癌症精准医学：从癌症筛查到药物选择和个性化免疫治疗。
Trends Pharmacol Sci. 2017 Jan;38(1):15-24. doi: 10.1016/j.tips.2016.10.013. Epub 2016 Nov 12.
9
Sex and Gender Influences on Cancer Immunotherapy Response.性别对癌症免疫治疗反应的影响。
Biomedicines. 2020 Jul 21;8(7):232. doi: 10.3390/biomedicines8070232.
10
The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy.癌症精准医学的路线图，结合先进的癌症检测技术和个性化免疫疗法的创新。
Jpn J Clin Oncol. 2019 Jul 1;49(7):596-603. doi: 10.1093/jjco/hyz073.
引用本文的文献
1
Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis.癌症患者接受免疫检查点抑制剂治疗的不良反应中的性别差异：MOUSEION-07 系统评价和荟萃分析。
Sci Rep. 2024 Nov 16;14(1):28309. doi: 10.1038/s41598-024-71746-z.
2
The Role of Estrogen and Estrogen Receptors in Head and Neck Tumors.雌激素及雌激素受体在头颈部肿瘤中的作用
Cancers (Basel). 2024 Apr 19;16(8):1575. doi: 10.3390/cancers16081575.
3
Treatment patterns, clinical outcomes, and healthcare resource use associated with advanced/metastatic lung cancer in China: protocol for a retrospective observational study.中国晚期/转移性肺癌的治疗模式、临床结局及医疗资源利用：一项回顾性观察性研究方案
Transl Lung Cancer Res. 2020 Dec;9(6):2460-2468. doi: 10.21037/tlcr-20-1269.
4
Differences in men and women suffering from CRSwNP and AERD in quality of life.慢性鼻-鼻窦炎伴鼻息肉和阿司匹林加重性呼吸系统疾病患者生活质量的差异。
Eur Arch Otorhinolaryngol. 2021 May;278(5):1419-1427. doi: 10.1007/s00405-020-06418-5. Epub 2020 Oct 15.
5
Sex and Gender Influences on Cancer Immunotherapy Response.性别对癌症免疫治疗反应的影响。
Biomedicines. 2020 Jul 21;8(7):232. doi: 10.3390/biomedicines8070232.
6
Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters.接受检查点抑制剂治疗的非小细胞肺癌患者中的可溶性程序性死亡配体1及其与代谢参数的相关性
Cancers (Basel). 2020 May 27;12(6):1373. doi: 10.3390/cancers12061373.
7
Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer.临床病理特征对晚期肺癌患者免疫检查点抑制剂联合传统治疗疗效的影响。
J Thorac Dis. 2019 Sep;11(9):3794-3807. doi: 10.21037/jtd.2019.09.19.
8
Non-invasive assessment of tumor PD-L1 status with circulating tumor cells.利用循环肿瘤细胞对肿瘤程序性死亡受体配体1（PD-L1）状态进行无创评估。
Ann Transl Med. 2018 Nov;6(Suppl 1):S48. doi: 10.21037/atm.2018.10.09.
本文引用的文献
1
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.癌症免疫疗法的疗效与患者性别：系统评价和荟萃分析。
Lancet Oncol. 2018 Jun;19(6):737-746. doi: 10.1016/S1470-2045(18)30261-4. Epub 2018 May 16.
2
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.肿瘤突变负荷与对PD-1抑制的反应率
N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.
3
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.PD-L1 免疫组织化学检测在肺癌中的应用：蓝图 PD-L1 IHC 检测比较项目第一阶段的结果。
J Thorac Oncol. 2017 Feb;12(2):208-222. doi: 10.1016/j.jtho.2016.11.2228. Epub 2016 Nov 29.
4
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.手术切除原发性肺腺癌中 PD-L1 蛋白表达的临床意义。
J Thorac Oncol. 2016 Nov;11(11):1879-1890. doi: 10.1016/j.jtho.2016.06.006. Epub 2016 Jun 23.
5
Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma.超深度靶向测序分析显示，肺癌腺癌的突变负担与性别及临床结局相关。
Oncotarget. 2016 Apr 19;7(16):22857-64. doi: 10.18632/oncotarget.8213.
6
Gender Disparity and Mutation Burden in Metastatic Melanoma.转移性黑色素瘤中的性别差异与突变负担
J Natl Cancer Inst. 2015 Aug 20;107(11). doi: 10.1093/jnci/djv221. Print 2015 Nov.
7
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.癌症免疫学。突变图谱决定非小细胞肺癌对程序性死亡受体1（PD-1）阻断治疗的敏感性。
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
8
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.程序性死亡受体配体1（PD-L1）表达作为癌症免疫治疗中的预测生物标志物
Mol Cancer Ther. 2015 Apr;14(4):847-56. doi: 10.1158/1535-7163.MCT-14-0983. Epub 2015 Feb 18.
9
Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.靶向黑色素瘤中的PD1/PD-L1轴：生物学原理、临床挑战与机遇
Crit Rev Oncol Hematol. 2014 Jan;89(1):140-65. doi: 10.1016/j.critrevonc.2013.08.002. Epub 2013 Aug 28.
10
Tumor immunotherapy directed at PD-1.针对程序性死亡受体1（PD-1）的肿瘤免疫疗法。
N Engl J Med. 2012 Jun 28;366(26):2517-9. doi: 10.1056/NEJMe1205943. Epub 2012 Jun 2.
Zotero 插件